Addendum to IMC Submission on Drugs for Rare Diseases
Innovative Medicines Canada provides Health Canada with additional input regarding IMC’s March 2021 consultation submission on drugs for rare diseases.
All Resources
Our resource hub to discover reports, policy papers and other forms of informative content
Filter by
PMPRB Notice and Comment Response
Innovative Medicines Canada opposes a July 15, 2021 proposal to change international price tests for existing medicines and their line extensions from the highest of the international schedule to the median.
2022 Federal Pre-Budget Consultation
Our industry calls on the federal government to implement measures under the Biomanufacturing and Life Sciences Strategy to build a more vibrant life sciences sector and enhance patients’ access to innovative medicines.
Proposed Guidelines Monitoring and Evaluation Plan
This submission responds to PMPRB’s consultation on its proposed Guideline Monitoring and Evaluation Plan GMEP, deeming it premature.
Towards a Value-based and Pan-Canadian Rare Disease Strategy
IMC proposes a value-based, pan-Canadian rare disease strategy, built in collaboration with provinces, patients, clinicians and industry to fill gaps and meet specific needs.
ISED Consultation on Biomanufacturing
IMC encourages the federal government to commit to building Canada’s domestic life sciences sector and manufacturing capacity. This follows IMC’s proposal in fall 2020 to establish a public-private biomanufacturing accelerator.
2021 Federal Pre-Budget Consultation
The industry calls on the federal government to delay implementation of PMPRB regulatory changes until the COVID-19 pandemic has abated. IMC urges the federal government to work with our industry to build a more vibrant life sciences sector – one that enhances patients’ access to innovative medicines and tackles the sector’s critical issues.
House of Commons Standing Committee on Health (HESA)
The industry campaigns to remove experimental “new economic factors” from regulations – the source of most stakeholder concerns amid 2020 PMPRB changes. IMC encourages government to delay implementation of changes until the COVID-19 pandemic has abated.
Pre-Budget Consultations in advance of the upcoming 2021 Federal Budget
IMC recommends striking a balance among affordability and access to innovative medicines and vaccines, allocating more funding and research incentives over five years, and developing a national life sciences strategy.